ReviewCardiovascular diabetology2020
Reappraisal on pharmacological and mechanical treatments of heart failure.
Review in Cardiovascular diabetology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- The efficacy of transcutaneous vagus nerve stimulation in heart failure management - a systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- Pooled it
- Comparative Safety and Efficacy of Eight Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.Frontiers in cardiovascular medicine · 2022Pooled it
- Reassessing Revascularization Strategies in Coronary Artery Disease and Type 2 Diabetes Mellitus.Frontiers in cardiovascular medicine · 2021Pooled it
- The role of long non-coding RNAs in cardiovascular diseases: A comprehensive review.Non-coding RNA research · 2025Review
- Generation of a medicine food homology formula and its likely mechanism in treatment of microvascular angina.Frontiers in pharmacology · 2024Article
- Comparison of American and European guidelines for cardio-oncology of heart failure.Heart failure reviews · 2023Review
- LuQi Formula relieves ventricular remodeling through improvement of HIF-1α-mediated intestinal barrier integrity.Chinese medicine · 2023Article
- Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors.Biomedicines · 2023Review
- Comprehensive analysis of endoplasmic reticulum stress-related mechanisms in type 2 diabetes mellitus.World journal of diabetes · 2023Article
- Investigating the effects of beta-blockers on circadian heart rhythm using heart rate variability in ischemic heart disease with preserved ejection fraction.Scientific reports · 2023Article
- Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism.Journal of cardiovascular translational research · 2023Review
- Sanwei sandalwood decoction improves function of the gut microbiota in heart failure.Frontiers in microbiology · 2023Article
- Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Coronary Heart Disease Complicating Chronic Heart Failure (Syndrome of Qi Deficiency with Blood Stasis): Study Protocol for a Randomized, Placebo-Controlled, Double-Blind and Multi-Centre Phase II Clinical Trial.International journal of general medicine · 2023Article
- Activation of the sigma-1 receptor exerts cardioprotection in a rodent model of chronic heart failure by stimulation of angiogenesis.Molecular medicine (Cambridge, Mass.) · 2022Article
- Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction.BMC cardiovascular disorders · 2022Article
- Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure.Cardiovascular diabetology · 2022Review
- Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.International journal of medical sciences · 2022Review
- Bioimpedance Vector Analysis for Heart Failure: Should We Put It on the Agenda?Frontiers in cardiovascular medicine · 2021Review
- Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE.Cardiovascular diabetology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a highly frequent disorder with considerable morbidity, hospitalization, and mortality; thus, it invariably places pressure on clinical and public health systems in the modern world. There have been notable advances in the definition, diagnosis, and treatment of HF, and newly developed agents and devices have been widely adopted in clinical practice. Here, this review first summarizes the current emerging therapeutic agents, including pharmacotherapy, device-based therapy, and the treatment of some common comorbidities, to improve the prognosis of HF patients. Then, we discuss and point out the commonalities and areas for improvement in current clinical studies of HF. Finally, we highlight the gaps in HF research. We are looking forward to a bright future with reduced morbidity and mortality from HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.